Tag: avrobio

January 18, 2019

AVROBIO Announces Acceptance of Investigational New Drug (IND) Application

AVROBIO (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy candidate for cystinosis, AVR-RD-04, is cleared...
November 1, 2018

VIDEO — Life Science Update October 2018

With October behind us, the Investing News Network (INN) has brought together some of the biggest stories in the life...
October 1, 2018

Avrobio’s Share Price Drops 50 Percent Amid Clinical Trial Updates

On Monday, the company released updates on two drugs in ongoing trials. The first drug is in a Phase 1...
October 1, 2018

AVROBIO Receives No Objection to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher Disease

AVROBIO (Nasdaq:AVRO) a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today...
October 1, 2018

AVROBIO Announces Updated Clinical Data for AVR-RD-01 Gene Therapy in Fabry Disease

AVROBIO (Nasdaq:AVRO) a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today...